We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Evaluate the Safety and Efficacy of Two Contraceptive Vaginal Rings Delivering a Daily Dose of 1500 or 2500 μg of CDB-2914

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00791297
Recruitment Status : Completed
First Posted : November 14, 2008
Last Update Posted : August 15, 2017
Sponsor:
Information provided by (Responsible Party):
Population Council

Tracking Information
First Submitted Date  ICMJE November 13, 2008
First Posted Date  ICMJE November 14, 2008
Last Update Posted Date August 15, 2017
Study Start Date  ICMJE October 2008
Actual Primary Completion Date September 2014   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: November 13, 2008)
The primary efficacy variable will be ovulation suppression measured by progesterone serum levels. [ Time Frame: All women will use the assigned CVR for 6 months ]
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: November 13, 2008)
  • Regular follow-up of follicle diameter will be made with USS to determine the timing of ovulation or, in the absence of ovulation, the fate of the dominant follicle. [ Time Frame: All women will use the assigned CVR for 6 months ]
  • Clinical safety will be evaluated and the effects on the endometrium will be measured. [ Time Frame: All women will use the assigned CVR for 6 months ]
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Study to Evaluate the Safety and Efficacy of Two Contraceptive Vaginal Rings Delivering a Daily Dose of 1500 or 2500 μg of CDB-2914
Official Title  ICMJE A Phase 2, Randomized Study to Evaluate the Safety and Efficacy of Two Contraceptive Vaginal Rings Delivering a Daily Dose of 1500 or 2500 μg of CDB-2914 on Inhibition of Ovulation, Endometrial Changes and Bleeding Patterns in Normal Cycling Women
Brief Summary

The purpose of this study is to to determine pharmacodynamic effects of a vaginal ring delivering either 1,500 or 2,500 μg of CDB-2914 per day during 6 months of treatment on:

  1. follicular function and inhibition of ovulation
  2. the endometrium
  3. bleeding patterns; and also to assess safety including effects on the endometrium
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Contraception
Intervention  ICMJE Drug: CDB-2914
Contraceptive Vaginal Rings delivering a daily dose of 1500 or 2500 μg of CDB-2914
Study Arms  ICMJE
  • Active Comparator: 1
    Contraceptive Vaginal Ring delivering a daily dose of 1500 μg of CDB-2914
    Intervention: Drug: CDB-2914
  • Active Comparator: 2
    Contraceptive Vaginal Ring delivering a daily dose of 2500 μg of CDB-2914
    Intervention: Drug: CDB-2914
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: August 11, 2017)
55
Original Estimated Enrollment  ICMJE
 (submitted: November 13, 2008)
60
Actual Study Completion Date  ICMJE September 2014
Actual Primary Completion Date September 2014   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Healthy women of reproductive age (21-40 years)
  • Not at risk for pregnancy based on one of the following
  • subject has undergone sterilization
  • subject is monogamous and her male partner has undergone sterilization
  • subject agrees to be abstinent for the entire duration of the study (Oregon site only)
  • subject does not have sex with men (Oregon site only)
  • Have regular menstrual cycles of 25-35 days duration
  • Have an intact uterus and both ovaries
  • Will be able to comply with the protocol
  • Capable of giving informed consent

Exclusion Criteria:

  • Women participating in another clinical trial
  • Women not living in the catchment area of the clinic
  • Known hypersensitivity to progestins or antiprogestins
  • Known hypersensitivity to silicone rubber
  • Any chronic disease
  • All contraindications to oral contraceptive use, including
  • Thrombophlebitis or thromboembolic disorders
  • Past history of deep vein thrombophlebitis or thromboembolic disorders
  • Past or current cerebrovascular or coronary artery disease
  • Migraine with focal aura
  • Known or suspected carcinoma of the breast
  • Carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia
  • Undiagnosed abnormal genital bleeding
  • Cholestatic jaundice of pregnancy or jaundice with prior pill use
  • Hepatic adenomas or carcinomas
  • Known or suspected pregnancy
  • Desire to get pregnant during the study (through the use of reproductive technology for sterilized women or vasectomy reversal for sterilized partners)
  • Breastfeeding
  • Undiagnosed vaginal discharge or vaginal lesions or abnormalities
  • Elevated Prolactin levels (above laboratory normal values)
  • Women with a current abnormal Pap
  • In accordance with the Bethesda system of classification smear suggestive of high-grade pre-cancerous lesion(s), including HGSIL, are excluded
  • Women with LGSIL or ASCUS/high-risk HPV positive may participate if further evaluated with colposcopy and biopsy and no evidence of a lesion with a severity > CIN I is present and/or endocervical curettage is negative
  • Women with a biopsy finding of CIN I should have follow up for this finding per standard of care; women are excluded it treatment is indicated
  • In accordance with other Pap class systems
  • Women with high grade dysplasia are excluded
  • Women with low grade dysplasia or CIN I interpretation on Pap smear may participate based on Investigator discretion and provided there is appropriate follow up in accordance with local standards of care
  • Known benign or malignant liver tumors; known active liver disease
  • Cancer (past history of any carcinoma or sarcoma)
  • Medically diagnosed severe depression currently or in the past
  • Known or suspected alcoholism or drug abuse
  • Abnormal serum fasting clinical chemistry values
  • Women with known abnormal thyroid status
  • Women with known impaired hypothalamic-pituitary-adrenal reserve
  • Average diastolic BP > 85 mm or systolic BP >135 mm Hg after 5-10 minutes rest
  • Body mass index(BMI) > 29.0
  • Smoking in women who are 35 years and over or will be 35 years during the course of the trial; women < 35 years who smoke greater than 15 cigarettes per day must be evaluated by the PI for inclusion based on risk factors that would increase their risk for CVD and thromboembolism, e.g. lipid levels, glucose level, BP, BMI, family history of CVD at a young age
  • Women with severe cystoceles or rectoceles
  • Use within the past 2 months of any implanted hormonal contraceptives including Mirena [progestin containing intrauterine system (IUS)] or Norplant (subdermal implant delivering LNG) NOTE: Removal of implanted hormonal contraceptives must have been for personal reasons unrelated to the purpose of enrollment in this study
  • Current use of a non-hormone containing IUD. NOTE: Removal of an IUD must have been for personal reasons unrelated to the purpose of enrollment in this study
  • Use of injectable contraceptives during the previous 3 months (e.g. Cyclofem) or 6 months (e.g. DMPA)
  • Women who do not have at least two progesterone measurements during the control cycle of ≥10nmol/L will be excluded from further participation in the study (See Section 13.41)
Sex/Gender  ICMJE
Sexes Eligible for Study: Female
Ages  ICMJE 21 Years to 40 Years   (Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Chile,   Dominican Republic,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00791297
Other Study ID Numbers  ICMJE Population Council #422
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Current Responsible Party Population Council
Original Responsible Party Regine Sitruk-Ware, Study Coordinator, Population Council
Current Study Sponsor  ICMJE Population Council
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE Not Provided
Investigators  ICMJE Not Provided
PRS Account Population Council
Verification Date August 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP